Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Linh Nguyen, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Paul Nguyen and Toni Choueiri.
Paul Nguyen
Connection Strength
11.594
Toni Choueiri
  1. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011 Dec 07; 306(21):2359-66.
    View in: PubMed
    Score: 0.487
  2. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41.
    View in: PubMed
    Score: 0.196
  3. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523.
    View in: PubMed
    Score: 0.188
  4. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154.
    View in: PubMed
    Score: 0.187
  5. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol. 2018 02 01; 29(2):386-391.
    View in: PubMed
    Score: 0.187
  6. The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. Eur Urol Focus. 2019 05; 5(3):474-481.
    View in: PubMed
    Score: 0.186
  7. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104.
    View in: PubMed
    Score: 0.177
  8. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343.
    View in: PubMed
    Score: 0.175
  9. Racial Disparities in Prostate Cancer Outcome among Prostate-Specific Antigen Screening Eligible Populations in the United States. Ann Oncol. 2017 Feb 08.
    View in: PubMed
    Score: 0.174
  10. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3.
    View in: PubMed
    Score: 0.171
  11. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700.
    View in: PubMed
    Score: 0.168
  12. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377.
    View in: PubMed
    Score: 0.168
  13. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol. 2016 09 20; 34(27):3267-75.
    View in: PubMed
    Score: 0.167
  14. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016 06 01; 34(16):1905-12.
    View in: PubMed
    Score: 0.165
  15. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8.
    View in: PubMed
    Score: 0.164
  16. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
    View in: PubMed
    Score: 0.161
  17. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22.
    View in: PubMed
    Score: 0.159
  18. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32.
    View in: PubMed
    Score: 0.158
  19. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85.
    View in: PubMed
    Score: 0.158
  20. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101.
    View in: PubMed
    Score: 0.157
  21. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35.
    View in: PubMed
    Score: 0.157
  22. Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 2015 Dec; 13(6):525-30.e1-3.
    View in: PubMed
    Score: 0.155
  23. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8.
    View in: PubMed
    Score: 0.155
  24. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015 Jul; 33(7):330.e19-25.
    View in: PubMed
    Score: 0.155
  25. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9.
    View in: PubMed
    Score: 0.152
  26. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
    View in: PubMed
    Score: 0.151
  27. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015 Jan; 13(1):61-8.
    View in: PubMed
    Score: 0.151
  28. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Mar; 93(3):257-76.
    View in: PubMed
    Score: 0.150
  29. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406.
    View in: PubMed
    Score: 0.150
  30. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65.
    View in: PubMed
    Score: 0.149
  31. Incidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282.
    View in: PubMed
    Score: 0.149
  32. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13.
    View in: PubMed
    Score: 0.148
  33. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9.
    View in: PubMed
    Score: 0.145
  34. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92.
    View in: PubMed
    Score: 0.145
  35. Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov; 92(2):123-32.
    View in: PubMed
    Score: 0.145
  36. Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014 Jul 01; 32(19):2025-30.
    View in: PubMed
    Score: 0.145
  37. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8.
    View in: PubMed
    Score: 0.144
  38. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91.
    View in: PubMed
    Score: 0.144
  39. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95.
    View in: PubMed
    Score: 0.144
  40. Refusal of curative radiation therapy and surgery among patients with cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):756-64.
    View in: PubMed
    Score: 0.144
  41. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21.
    View in: PubMed
    Score: 0.143
  42. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014 May 15; 120(10):1532-9.
    View in: PubMed
    Score: 0.142
  43. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014 May; 113(5b):E67-74.
    View in: PubMed
    Score: 0.142
  44. Marital status and survival in patients with cancer. J Clin Oncol. 2013 Nov 01; 31(31):3869-76.
    View in: PubMed
    Score: 0.138
  45. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer. 2013 Jun 25; 108(12):2478-84.
    View in: PubMed
    Score: 0.135
  46. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol. 2013 Aug; 24(8):2092-7.
    View in: PubMed
    Score: 0.134
  47. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):415-21.
    View in: PubMed
    Score: 0.134
  48. Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate. J Clin Oncol. 2013 Feb 20; 31(6_suppl):161.
    View in: PubMed
    Score: 0.132
  49. Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials. J Clin Oncol. 2013 Feb 20; 31(6_suppl):353.
    View in: PubMed
    Score: 0.132
  50. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81(1):130-4.
    View in: PubMed
    Score: 0.131
  51. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73.
    View in: PubMed
    Score: 0.125
  52. Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone. J Clin Oncol. 2012 Feb 10; 30(5_suppl):38.
    View in: PubMed
    Score: 0.123
  53. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):1411-6.
    View in: PubMed
    Score: 0.118
  54. Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology. 2011 Jul; 78(1):93-8.
    View in: PubMed
    Score: 0.117
  55. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011 Apr 20; 29(12):1517-24.
    View in: PubMed
    Score: 0.116
  56. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.
    View in: PubMed
    Score: 0.114
  57. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011 Jun; 22(6):1404-1412.
    View in: PubMed
    Score: 0.113
  58. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology. 2010 Nov; 76(5):1201-5.
    View in: PubMed
    Score: 0.111
  59. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1318-22.
    View in: PubMed
    Score: 0.110
  60. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010 Apr 15; 116(8):1887-92.
    View in: PubMed
    Score: 0.109
  61. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5.
    View in: PubMed
    Score: 0.107
  62. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet. 2021 11; 258-259:61-68.
    View in: PubMed
    Score: 0.060
  63. Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urol Oncol. 2021 02; 39(2):130.e17-130.e24.
    View in: PubMed
    Score: 0.057
  64. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol. 2020 09; 38(9):735.e9-735.e15.
    View in: PubMed
    Score: 0.055
  65. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
    View in: PubMed
    Score: 0.054
  66. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
    View in: PubMed
    Score: 0.053
  67. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
    View in: PubMed
    Score: 0.052
  68. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
    View in: PubMed
    Score: 0.051
  69. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
    View in: PubMed
    Score: 0.051
  70. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
    View in: PubMed
    Score: 0.050
  71. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
    View in: PubMed
    Score: 0.049
  72. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
    View in: PubMed
    Score: 0.049
  73. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
    View in: PubMed
    Score: 0.047
  74. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
    View in: PubMed
    Score: 0.047
  75. Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e96-e97.
    View in: PubMed
    Score: 0.047
  76. Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e100-e101.
    View in: PubMed
    Score: 0.046
  77. Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64.
    View in: PubMed
    Score: 0.045
  78. Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. Eur Urol. 2018 Mar; 73(3):452-461.
    View in: PubMed
    Score: 0.045
  79. Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451.
    View in: PubMed
    Score: 0.045
  80. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. J Urol. 2017 12; 198(6):1295-1300.
    View in: PubMed
    Score: 0.045
  81. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol. 2018 02; 73(2):262-270.
    View in: PubMed
    Score: 0.045
  82. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
    View in: PubMed
    Score: 0.044
  83. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
    View in: PubMed
    Score: 0.043
  84. Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98.
    View in: PubMed
    Score: 0.042
  85. The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Prev Med. 2016 08; 89:140-145.
    View in: PubMed
    Score: 0.041
  86. Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
    View in: PubMed
    Score: 0.041
  87. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016 Apr; 2(4):500-7.
    View in: PubMed
    Score: 0.041
  88. Data on Medicare eligibility and cancer screening utilization. Data Brief. 2016 Jun; 7:679-81.
    View in: PubMed
    Score: 0.041
  89. The impact of Medicare eligibility on cancer screening behaviors. Prev Med. 2016 Apr; 85:47-52.
    View in: PubMed
    Score: 0.040
  90. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
    View in: PubMed
    Score: 0.040
  91. Asian Americans and prostate cancer: A nationwide population-based analysis. Urol Oncol. 2016 May; 34(5):233.e7-15.
    View in: PubMed
    Score: 0.040
  92. Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA. 2015 Nov 17; 314(19):2077-9.
    View in: PubMed
    Score: 0.040
  93. Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. J Urol. 2016 04; 195(4 Pt 1):913-8.
    View in: PubMed
    Score: 0.040
  94. Suicide and accidental deaths among patients with non-metastatic prostate cancer. BJU Int. 2016 Aug; 118(2):286-97.
    View in: PubMed
    Score: 0.040
  95. Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2015 Sep; 13(9):1131-8.
    View in: PubMed
    Score: 0.039
  96. Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urol Oncol. 2015 Dec; 33(12):503.e7-15.
    View in: PubMed
    Score: 0.039
  97. Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17.
    View in: PubMed
    Score: 0.039
  98. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged =66 years. Eur J Surg Oncol. 2015 Nov; 41(11):1529-39.
    View in: PubMed
    Score: 0.039
  99. An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. BJU Int. 2015 Dec; 116(6):911-9.
    View in: PubMed
    Score: 0.039
  100. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Aug; 95(2):251-63.
    View in: PubMed
    Score: 0.038
  101. Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. J Natl Cancer Inst. 2015 Jun; 107(6):djv054.
    View in: PubMed
    Score: 0.038
  102. Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology. 2015 Feb; 85(2):343-9.
    View in: PubMed
    Score: 0.038
  103. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015 May; 94(2):228-37.
    View in: PubMed
    Score: 0.038
  104. The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015 Jan; 33(1):17.e9-17.e18.
    View in: PubMed
    Score: 0.037
  105. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. Eur Urol. 2015 Jul; 68(1):32-9.
    View in: PubMed
    Score: 0.037
  106. Mental health outcomes in elderly men with prostate cancer. Urol Oncol. 2014 Nov; 32(8):1333-40.
    View in: PubMed
    Score: 0.037
  107. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol. 2014 May 10; 32(14):1419-26.
    View in: PubMed
    Score: 0.036
  108. Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. BMJ Open. 2014 Mar 23; 4(3):e003921.
    View in: PubMed
    Score: 0.036
  109. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. 2014 Dec; 66(6):1125-32.
    View in: PubMed
    Score: 0.035
  110. Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int. 2013 Aug; 112(4):E273-80.
    View in: PubMed
    Score: 0.033
  111. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012 Jun; 61(6):1239-44.
    View in: PubMed
    Score: 0.031
  112. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer. 2011 Nov 01; 117(21):4846-54.
    View in: PubMed
    Score: 0.029
  113. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan; 185(1):116-20.
    View in: PubMed
    Score: 0.028
  114. Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology. 2011 Feb; 77(2):402-6.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.